Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) EBT (2016 - 2025)

Fate Therapeutics' EBT history spans 14 years, with the latest figure at -$32.5 million for Q4 2025.

  • For Q4 2025, EBT rose 43.84% year-over-year to -$32.5 million; the TTM value through Dec 2025 reached -$136.7 million, up 29.19%, while the annual FY2025 figure was -$136.7 million, 29.19% up from the prior year.
  • EBT reached -$32.5 million in Q4 2025 per FATE's latest filing, down from -$32.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$24.9 million in Q1 2023 to a low of -$84.6 million in Q3 2022.
  • Average EBT over 5 years is -$51.1 million, with a median of -$46.8 million recorded in 2023.
  • Peak YoY movement for EBT: tumbled 109.01% in 2021, then surged 66.38% in 2023.
  • A 5-year view of EBT shows it stood at -$69.1 million in 2021, then grew by 10.92% to -$61.5 million in 2022, then rose by 29.05% to -$43.7 million in 2023, then crashed by 32.55% to -$57.9 million in 2024, then soared by 43.84% to -$32.5 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's EBT are -$32.5 million (Q4 2025), -$32.2 million (Q3 2025), and -$34.0 million (Q2 2025).